Professional Titles
- Associate Director of Translational Research
- Professor of Medicine
- Director of Personalized Medicine, Division of Medical Oncology
- Margaret and Hugh Stapp Endowed Chair for Cancer Research
Publications
- Vaddi P, Strange A, Liu L, Davis S, Yusuff S, Flaherty K, Jara K, Kramer J, Archer C, Pine SR, Wang W, Nakamura T, Sabaawy HE. An evolutionary-conserved molecular signature of cell senescence. Systems Approaches to Cancer Biology, 2025. sacbmeeting.org/public/PosterPresentationAbstracts2025.pdf, page 25.
- Strange A, Liu L, Vaddi P, Lee S, Gao B, Menon Ravindran D, Merrick D, Aisner S, van Bokhoven A, Patil T, Camidge DR, Pine SR, and Sabaawy HE. High plex single cell spatial signatures of lung cancer resistance to therapy. Systems Approaches to Cancer Biology, 2025. sacbmeeting.org/public/PosterPresentationAbstracts2025.pdf, page 40.
- Ma J, Ravindran Menon D, Wang Z, Mintzlaff D, Rock H, Giesy L, Huang CA, Mathes DW, Nydam T, Pomfret EA, Camidge DR, Sabaawy HE, Pine SR, Wang Z. Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer. bioRxiv. 2025 Dec 26. PubMed PMID: 41497639
- Liu L, Davis S, Yusuff S, Strange A, Zhuang Y, Vaddi P, Flaherty K, Jara K, Kramer J, Archer C, Lee S, Gao B, van Bokhoven A, Wang W, Pine SR, Nakamura T, Sabaawy HE. Evolutionary conserved reciprocal senescence and tumor suppressor signals limit lifetime cancer. BioRxiv 2025. Doi: 10.1101/2024.12.28.630560. ID: 630560.
- Giesy L, Liu L, Zhuang Y, Vaddi P, Merrick D, Patil T, DeGregori J, Sabaawy HE, Camidge DR, Pine S. Assessment of bypass drug resistance mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens. Annual Lung Cancer SPORE Meeting. The University of Texas Lung SPORE. MD Anderson Cancer Center, Houston, Texas, June 10-11, 2025.
- Strange A, Liu L, Vaddi P, Pine SR and Sabaawy HE. High plex single cell spatial signatures of lung cancer resistance to therapy. Systems Approaches to Cancer Biology – 2025. In "Applying Systems Biology to Understand Cancer Mechanisms and Develop Therapeutic Strategies." February 10-12, 2025.
- Liu L, Vaddi P, Strange A, Liu L, Davis S, Yusuff S, Flaherty K, Jara K, Kramer J, Archer C, Pine SR, Wang W, Nakamura T, and Sabaawy HE. An evolutionary-conserved molecular signature of cell senescence. Systems Approaches to Cancer Biology – 2025. In "Applying Systems Biology to Understand Cancer Mechanisms and Develop Therapeutic Strategies." February 10-12, 2025.
- Liu L, Davis S, Yusuff S, Strange A, Zhuang Y, Vaddi P, Flaherty K, Jara K, Kramer J, Archer C, Lee S, Gao B, van Bokhoven A, Wang W, Pine SR, Nakamura T, Sabaawy HE. Evolutionary conserved reciprocal senescence and tumor suppressor signals limit lifetime cancer. BioRxiv 2024. Doi: 10.1101/2024.12.28.630560. ID: 630560.
- Pine SR, Watson AS, Patil T, Schenk EL, Merrick D, Camidge DR, and Sabaawy HS. Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing. Journal of Clinical Oncology, Volume 42, Number 16_suppl. https://doi.org/10.1200/JCO.2024.42.16_suppl.e20521.
- Liu L, Strange S, Lee S, Gao B, Merrick D, Patil T, DeGregori J, Camidge DR, Pine SR, and Sabaawy HE. Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens. Cancer Research, 2024, Volume 84, Supplement 6: 6496. https://doi.org/10.1158/1538-7445.AM2024-6496
- Liu L, Davis S, Yusuff S, Strange A, Zhuang Y, Vaddi P, Flaherty K, Jara K, Kramer J, Archer C, Lee S, Gao B, van Bokhoven A, Wang W, Pine SR, Nakamura T, Sabaawy HE. Evolutionary conserved reciprocal senescence and tumor suppressor signals limit lifetime cancer. BioRxiv 2024. Doi: 10.1101/2024.12.28.630560. ID: 630560.
- Pine SR, Watson AS, Patil T, Schenk EL, Merrick D, Camidge DR, and Sabaawy HS. Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing. Journal of Clinical Oncology, Volume 42, Number 16_suppl. https://doi.org/10.1200/JCO.2024.42.16_suppl.e20521.
- Liu L, Strange S, Lee S, Gao B, Merrick D, Patil T, DeGregori J, Camidge DR, Pine SR, and Sabaawy HE. Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens. Cancer Research, 2024, Volume 84, Supplement 6: 6496. https://doi.org/10.1158/1538-7445.AM2024-6496.
- Sabaawy HE, Broggini M, Gupta SK. Patient-derived tumor models for drug development. Front Oncol. 2023;13:1243534. PubMed PMID: 37483498
- Zhong H, Lu W, Tang Y, Wiel C, Wei Y, Cao J, Riedlinger G, Papagiannakopoulos T, Guo JY, Bergo MO, Kang Y, Ganesan S, Sabaawy HE, Pine SR. SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity. Oncogene. 2023 Jun;42(27):2183-2194. PubMed PMID: 37258742
- Laureano AS, Flaherty K, Hinman AM, Jadali A, Nakamura T, Higashijima SI, Sabaawy HE, Kwan KY. shox2 is required for vestibular statoacoustic neuron development. Biol Open. 2022 Dec 15;11(12). PubMed PMID: 36594417
- Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 Sep 6;21(9):1381-1392. PubMed PMID: 35732569
- Kim IY, Mitrofanova A, Panja S, Sterling J, Srivastava A, Kim J, Kim S, Singer EA, Jang TL, Ghodoussipour S, Saraiya B, Mayer T, Sabaawy HE, Yuh B, Byun SS, Kim WJ, Horie S. Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate Int. 2022 Jun;10(2):75-79. PubMed PMID: 35510081
- Al-Zubaydi F, Gao D, Kakkar D, Li S, Holloway J, Szekely Z, Chan N, Kumar S, Sabaawy HE, Love S, Sinko PJ. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy. Drug Deliv Transl Res. 2022 Jan;12(1):240-256. PubMed PMID: 33590464
- Sabaawy, HE, Wang, Z, Camidge, DR, and Pine SR. CD47 Biology and Therapeutic Targeting in Lung Cancer. Research Topic Spotlight: Advancing Excellence in Thoracic Oncology. Frontiers in Oncology, 2026 (In press).
- Ingersoll, S, Trouth, A, Carlos Angel, J, Luo, X, Espinoza, A, Wen, J, Tucker, J, Astatike, K, Sabaawy, HE, Kutateladze, TG, Wu, TP, Yao, T, Lu, C, Ramachandran, S and Ren, X. Self-clustering of three CBX2 proteins drives PRC2 to promote facultative heterochromatinization of Polycomb target genes. Molecular Cell, 2026 (In Press).
- Liu L, Davis S, Yusuff S, Strange A, Zhuang Y, Vaddi P, Ingersoll S, Flaherty K, Jara K, Kramer J, Archer C, Lee S, Gao B, van Bokhoven A, Wang W, Pine SR, Nakamura T, Sabaawy HE. INK4 and TP53 coordinated senescence and tumor suppressor signals limit lifetime cancer. Cell Research (Under review).
- Ma J, Ravindran Menon D, Wang Z, Mintzlaff D, Rock H, Giesy L, Huang CA, Mathes DW, Nydam T, Pomfret EA, Camidge DR, Sabaawy HE, Pine SR, Wang Z. Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer. Cancer Research Communication (Under review).
Professional Memberships
- American Society of Clinical Oncology (ASCO), Full member
- American Association of Cancer Research (AACR), Full member
Practice Locations
University of Colorado Cancer Center - Anschutz Medical Campus1665 Aurora Ct
Aurora, CO 80045
720-848-0300
Hospital Affiliation
- University of Colorado Hospital
Clinical Interests
Personalized Medicine, Molecular Diagnostics, Immunotherapy, Precision Therapy
Personalized Medicine, Molecular Diagnostics, Immunotherapy, Precision Therapy